---
title: "IDEAYA Biosciences: Buy Rating Reiterated as Precision Oncology Pipeline Advances and $62 Price Target Maintained"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293931866.md"
description: "LifeSci Capital analyst Charles Zhu reiterated a Buy rating on IDEAYA Biosciences with a $62 price target. The recommendation is driven by the advancement of its precision oncology pipeline, specifically the initiation of IDE892 monotherapy expansion in MTAP-deleted cancers. Key factors include rapid dose cohort progression, strong drug profile, and multiple combination strategies, supported by a 4.7-year cash runway."
datetime: "2026-07-27T11:55:17.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293931866.md)
  - [en](https://longbridge.com/en/news/293931866.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293931866.md)
generator: "portal-rs"
---

# IDEAYA Biosciences: Buy Rating Reiterated as Precision Oncology Pipeline Advances and $62 Price Target Maintained

LifeSci Capital analyst Charles Zhu maintained a Buy rating on IDEAYA Biosciences today and set a price target of $62.00.

### Claim 55% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

Charles Zhu has given his Buy rating due to a combination of factors that underscore IDEAYA’s advancing precision oncology pipeline and solid execution. He views the initiation of IDE892 monotherapy expansion in MTAP-deleted pancreatic and non-small cell lung cancers as a meaningful step, particularly given the rapid progression through dose cohorts and achievement of target drug exposure levels.

He also highlights IDE892’s differentiated profile, including strong MTA-selective PRMT5 activity, limited brain penetration to reduce CNS risk, and a favorable outlook on drug–drug interactions versus competing agents. In parallel, IDEAYA is pursuing multiple combination strategies, planning a pan-RAS regimen and future CDKN2A development, all supported by an estimated 4.7 years of cash runway, which in his view justifies maintaining the $62 price target and Buy recommendation.

### Related Stocks

- [IDYA.US](https://longbridge.com/en/quote/IDYA.US.md)

## Related News & Research

- [Wedbush Keeps Their Buy Rating on IDEAYA Biosciences (IDYA)](https://longbridge.com/en/news/296510282.md)
- [AI isn’t close to curing cancer. This startup says it knows what it will take.](https://longbridge.com/en/news/296352961.md)
- [TG Therapeutics Conference: 908 Devices Bets on Handheld Drug, Chemical Detection](https://longbridge.com/en/news/296165366.md)
- [Is Royalty Pharma (RPRX) Undervalued On Its $100 Million Zealand Pharma Royalty Deal?](https://longbridge.com/en/news/296647266.md)
- [07:45 ETIU Health launches theranostics center of excellence to expand personalized treatments for patients with cancer](https://longbridge.com/en/news/296350151.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**